Table 3.
Base-case results using a 9-valent pneumococcal conjugate vaccine (PCV9)
| Model outcomes | No vaccination | Vaccination (PCV9) | Reduction |
|---|---|---|---|
| Pneumonia (primary endpoint) | 5,039 | 3,635 | 27.9% |
| Pneumonia (non-primary endpoint) | 25,123 | 25,758 | -2.5% |
| Pneumonia (all endpoints) | 30,161 | 29,393 | 2.5% |
| Meningitis | 46 | 40 | 13.2% |
| Sepsis | 21 | 18 | 13.2% |
| Hospitalization (primary endpoint pneumonia) | 2,670 | 1,926 | 27.9% |
| Outpatient visit (primary endpoint pneumonia) | 2,368 | 1,708 | 27.9% |
| Hospitalization (all endpoints of pneumonia) | 7,519 | 6,898 | 8.3% |
| Hospitalization (all diseases) | 7,586 | 6,956 | 8.3% |
| Pneumonia (primary endpoint) deaths | 151 | 109 | 27.9% |
| Pneumonia (non-primary endpoint) deaths | 276 | 283 | -2.5% |
| Pneumonia (all endpoints) deaths | 428 | 392 | 8.2% |
| Meningitis deaths | 16 | 14 | 14.7% |
| Sepsis deaths | 7 | 6 | 13.1% |
| DALYs (K = 0)a | 182,630 | 181,630 | 0.5% |
| Costsa (2005 US$) | 233,100 | 902,040 | -- |
| ICER (2005 US$/DALY averted) | -- | 670 | -- |
| ICER expressed as % per capita GDPb | 190% | ||
DALY: disability-adjusted life year, ICER: incremental cost-effectiveness ratio.
a discounted at 3%.
b $360 (in 2005 US$) in The Gambia for 2008.